Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer

Ovarian cancer is one of the most lethal of woman cancers, and its clinical therapeutic outcome currently is unsatisfied. Dinaciclib, a novel small molecule inhibitor of CDK1, CDK2, CDK5 and CDK9, is assessed in clinical trials for the treatment of several types of cancers. In this study, we investi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiu-Xiu, Xie, Feng-Feng, Zhu, Xiu-Jie, Lin, Feng, Pan, Shi-Shi, Gong, Li-Hua, Qiu, Jian-Ge, Zhang, Wen-Ji, Jiang, Qi-Wei, Mei, Xiao-Long, Xue, You-Qiu, Qin, Wu-Ming, Shi, Zhi, Yan, Xiao-Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558126/
https://www.ncbi.nlm.nih.gov/pubmed/25962959

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558126/
https://www.ncbi.nlm.nih.gov/pubmed/25962959

Ejemplares similares